Predominantly expressed in the liver, intestine, and kidney, PCSK9 was first recognized as a key regulator of lipid metabolism when gain-of-function mutations in its gene were linked to familial hypercholesterolemia and an increased risk of coronary artery disease [18]. Here, PCSK9 is linked to familial hypercholesterolemia.